Anzeige
Mehr »
Mittwoch, 22.04.2026 - Börsentäglich über 12.000 News
BREAKING: Pacifica liefert hochgradige Treffer - Phase II trifft genau ins Ziel
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N9D9 | ISIN: US60770K1079 | Ticker-Symbol: 0QF
Tradegate
21.04.26 | 21:53
45,925 Euro
-0,67 % -0,310
1-Jahres-Chart
MODERNA INC Chart 1 Jahr
5-Tage-Chart
MODERNA INC 5-Tage-Chart
RealtimeGeldBriefZeit
46,14046,22021.04.
46,17046,29521.04.

Aktuelle News zur MODERNA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01:30Moderna begins phase 3 trial of H5 bird flu vaccine candidate2
MODERNA Aktie jetzt für 0€ handeln
01:02Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate419Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April...
► Artikel lesen
DiEurope Clears First Flu/COVID Combo Shot From Moderna10
DiModerna granted EU nod for combined COVID-19 and flu vaccine9
DiModerna, Inc.: Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting242Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on...
► Artikel lesen
DiModerna erhält EU-Zulassung für Grippe-COVID-Kombi-Impfstoff12
DiEuropean Commission approves Moderna's flu-COVID combo vaccine4
DiModerna, Inc.: Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19269mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will be made available in the European Union, subject...
► Artikel lesen
DiModerna, Inc.: Moderna to Present at Upcoming Conferences in May 2026224CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:BofA Securities 2026 Healthcare Conference...
► Artikel lesen
MoSanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike11
MoModerna's Quarterly Earnings Preview: What You Need to Know17
SoSanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study727PARIS (dpa-AFX) - Sanofi's (SNY, SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest...
► Artikel lesen
FrModerna-Krebstherapie erzielt 83 % Ansprechrate bei Melanom-Studie49
FrModerna's melanoma therapy shows 83% response rate in trial20
FrModerna, Inc.: Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting578The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TPS>1%)...
► Artikel lesen
FrBAG veröffentlicht Verträge: Eine Milliarde für Moderna-Impfstoff: War das zu teuer?16
DoBAG schafft volle Transparenz: Moderna und Novavax: Bund zahlte eine Milliarde für Impfstoffe29
15.04.Moderna, Inc.: Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026332CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its...
► Artikel lesen
15.04.Moderna - MRNA: Impfstoff-Aktie mit mega-starkem Comeback!881+ 100 Prozent in 6 Monaten! mrRNA-Impfstoffe gegen Krebs, Grippe & RSV bei Moderna in der Pipeline! Neue Rallye trotz US-Gesundheitsminister Robert F. Kennedy? Moderna (MRNA) - ISIN US60770K1079 Rückblick:...
► Artikel lesen
08.04.Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?64
Weiter >>
449 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
6,2,25